Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Average (2016 - 2025)

Historic Equity Average for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to $380.4 million.

  • Myriad Genetics' Equity Average fell 4831.54% to $380.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.4 million, marking a year-over-year decrease of 4831.54%. This contributed to the annual value of $742.2 million for FY2024, which is 1106.65% down from last year.
  • Myriad Genetics' Equity Average amounted to $380.4 million in Q3 2025, which was down 4831.54% from $546.5 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Equity Average ranged from a high of $968.2 million in Q4 2021 and a low of $380.4 million during Q3 2025
  • Moreover, its 5-year median value for Equity Average was $785.2 million (2023), whereas its average is $795.0 million.
  • As far as peak fluctuations go, Myriad Genetics' Equity Average surged by 920.74% in 2022, and later plummeted by 4831.54% in 2025.
  • Over the past 5 years, Myriad Genetics' Equity Average (Quarter) stood at $968.2 million in 2021, then dropped by 6.92% to $901.2 million in 2022, then decreased by 18.63% to $733.3 million in 2023, then dropped by 2.3% to $716.4 million in 2024, then crashed by 46.89% to $380.4 million in 2025.
  • Its last three reported values are $380.4 million in Q3 2025, $546.5 million for Q2 2025, and $703.0 million during Q1 2025.